Compare POET & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | TNDM |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2008 | 2013 |
| Metric | POET | TNDM |
|---|---|---|
| Price | $8.80 | $23.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 11.5M | 2.2M |
| Earning Date | 08-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $848.96 | $8.11 |
| Revenue Next Year | $700.00 | $11.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $3.87 | $10.25 |
| 52 Week High | $20.65 | $29.65 |
| Indicator | POET | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 73.47 |
| Support Level | $6.40 | $19.70 |
| Resistance Level | $9.15 | $24.23 |
| Average True Range (ATR) | 0.63 | 1.34 |
| MACD | 0.31 | 0.50 |
| Stochastic Oscillator | 88.38 | 91.82 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.